ArticleNature2025
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins.ChemMedChem · 2026Review
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Substrate-Selective Inhibition of the SARS-CoV-2 Papain-Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Direct lipid interactions control SARS-CoV-2 M protein conformational dynamics and virus assembly.Nature communications · 2026Article
- Coronavirus M Protein Hijacks Toll-Interacting Protein (TOLLIP) to Suppress NF-κB Signaling and Promote Immune Evasion.MedComm · 2026Article
- Rational Design of Broad-Spectrum Anti-Enteroviral Molecular Glues Targeting Enteroviral RNAi Suppressors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research.Microbial biotechnology · 2026Review
- Coronavirus M protein disperses the trans-Golgi network and inhibits anterograde protein trafficking in the secretory pathway.PLoS pathogens · 2026Article
- Inhibiting the interaction between the mitochondrial receptor Tom70 and SARS CoV 2 Orf9b with small molecules.bioRxiv : the preprint server for biology · 2026Article
- Beyond assembly: functions of the coronavirus M protein.Virology journal · 2026Review
- Potency ofThe Kobe journal of medical sciences · 2026Article
- Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes.PLoS computational biology · 2026Article
- Clues to Long COVID Linked to Virulence and Infectivity Found in Shell Proteins.Advances in respiratory medicine · 2026Review
- Targeting the host factor HGS-viral membrane protein interaction in coronavirus infection.The Journal of clinical investigation · 2026Article
- SARS-CoV-2 membrane protein biogenesis.bioRxiv : the preprint server for biology · 2026Article
- DABPU-DE targeting host adipose triglyceride lipase provides broad-spectrum anti-coronavirus effectsFrontiers in pharmacology · 2026Article
- From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.Neuroscience applied · 2026Review
- Computational modelling of the equine arteritis virus GP5/M Dimer: Implications for immune evasion and virulence.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Ellen Van DammeGlobal Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium.
Pravien Abeywickrema *Discovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.
Yanting Yin *Discovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.
Jiexiong Xie *Global Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium.
Sofie Jacobs *Global Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium.ORCID 0000-0001-8657-6841
Mandeep Kaur MannGlobal Public Health R&D, Janssen Research & Development, Spring House, PA, USA.ORCID 0000-0002-8252-6107
Jordi DoijenGlobal Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium.ORCID 0000-0002-1707-0174
Robyn MillerDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.
Madison PiassekDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.
Simone MarsiliTherapeutics Discovery, Janssen-Cilag, Toledo, Spain.
Murali SubramanianTranslational PK/PD & Investigative Toxicology (TPPIT), Janssen Research & Development, Beerse, Belgium.
Leah GottliebDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.
Rana AbdelnabiVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0001-9771-7312
Michiel Van GoolTherapeutics Discovery, Janssen-Cilag, Toledo, Spain.ORCID 0000-0001-5424-1377
Nick Van den BroeckCharles River Laboratories, Beerse, Belgium.ORCID 0000-0001-5900-4813
Ines De PauwCharles River Laboratories, Beerse, Belgium.
Annick DielsDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Beerse, Belgium.
Peter VermeulenDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Beerse, Belgium.
Koen TemmermanDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Beerse, Belgium.
Trevor ScobeyDepartment of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA.
Melissa MattocksDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA.ORCID 0000-0002-4760-4923
Dirk JochmansVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-9265-6028
Steven De JongheVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-3872-6558
Pieter LeyssenVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-7537-1688
Winston ChiuVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0001-5236-623X
Mayra Diosa ToroVirology Section, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Marleen ZwaagstraVirology Section, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Anouk A LeijsMolecular Virology Laboratory, Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Heidi L M De GruyterMolecular Virology Laboratory, Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Christophe BuyckIn Silico Discovery (ISD), Computer-Aided Drug Design (CADD), Janssen Pharmaceutica, Beerse, Belgium.
Klaas Van Den HeedeGlobal Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium.
Frank JacobsTranslational PK/PD & Investigative Toxicology (TPPIT), Janssen Research & Development, Beerse, Belgium.ORCID 0000-0002-5977-3943
Christel Van den EyndeGlobal Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium.
Laura ThijsCharles River Laboratories, Beerse, Belgium.
Valerie RaeymaekersCharles River Laboratories, Beerse, Belgium.
Seth MillerDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.
Amanda Del RosarioDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.ORCID 0000-0001-6107-7149
Johan NeytsVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-0033-7514
Danielle PeetersDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Beerse, Belgium.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA.ORCID 0000-0001-6827-8701
Frank J M van KuppeveldVirology Section, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-5800-749X
Eric J SnijderMolecular Virology Laboratory, Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-3297-2309
Martijn J van HemertMolecular Virology Laboratory, Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Mario MonshouwerTranslational PK/PD & Investigative Toxicology (TPPIT), Janssen Research & Development, Beerse, Belgium.
Sujata SharmaDiscovery Technologies & Molecular Pharmacology, Janssen Research & Development, Spring House, PA, USA.ORCID 0000-0002-7588-2939
Ruxandra Draghia-AkliGlobal Public Health R&D, Janssen Research & Development, Spring House, PA, USA. rdraghia@gmail.com.ORCID 0000-0001-6372-4039
Anil KoulGlobal Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium. anil.koul@lshtm.ac.uk.ORCID 0009-0009-5542-4568
Marnix Van LoockGlobal Public Health R&D, Janssen Pharmaceutica, Beerse, Belgium. mvloock@its.jnj.com.ORCID 0000-0003-4151-4588
Funding
Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5MNIAID NIH HHS U19 AI171292
Abstract
The membrane (M) protein of betacoronaviruses is well conserved and has a key role in viral assembly
Indexed as
Antiviral AgentsCoronavirus M ProteinsCOVID-19 Drug TreatmentSARS-CoV-2Viral Matrix ProteinsAnimalsBinding SitesChiropteraCOVID-19CricetinaeCryoelectron MicroscopyDisease Models, AnimalFemaleHumansLungMaleAntiviral AgentsCoronavirus M Proteinsmembrane protein, SARS-CoV-2Viral Matrix Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.